- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06448754
Estudio exploratorio de plataforma de fase II de regímenes de cebado Volrustomig (eVOLVE-01)
Un estudio abierto de fase II para evaluar la seguridad, tolerabilidad, farmacocinética, inmunogenicidad y actividad antitumoral de los regímenes de preparación de Volrustomig en combinación con otros agentes anticancerígenos en participantes con tumores sólidos (eVOLVE-01)
Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This Phase II, platform, open-label, multicenter study will evaluate the efficacy, safety, and tolerability of volrustomig in combination with anticancer drugs in various solid tumor types.
This platform study currently includes 2 substudies:
Substudy 1: metastatic non-small cell lung cancer (mNSCLC) (non-squamous [NSQ]). Participants will be randomized in two treatment arms: Arm 1A and Arm 1B.
Substudy 2: mNSCLC (squamous [SQ] or NSQ). Participants will enroll to the Arm 2A only.
All arms will test a volrustomig dosing in combination with chemotherapy.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Seongnam, Corea del Sur, 13620
- Research Site
-
Seoul, Corea del Sur, 03722
- Research Site
-
Suwon, Corea del Sur, 16247
- Research Site
-
-
-
-
-
A Coruña, España, 15009
- Research Site
-
Alcorcón, España, 28922
- Research Site
-
Barcelona, España, 08041
- Research Site
-
Madrid, España, 28041
- Research Site
-
Málaga, España, 29004
- Research Site
-
Pamplona, España, 31008
- Research Site
-
Santander, España, 39008
- Research Site
-
Santiago de Compostela, España, 15706
- Research Site
-
Valencia, España, 46026
- Research Site
-
Valencia, España, 46015
- Research Site
-
-
-
-
California
-
Los Angeles, California, Estados Unidos, 90067
- Research Site
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27514
- Research Site
-
-
-
-
-
Bois-Guillaume, Francia, 76031
- Research Site
-
Caen, Francia, 14076
- Research Site
-
Dijon, Francia, 21079
- Research Site
-
Montpellier, Francia, 34070
- Research Site
-
-
-
-
-
Batumi, Georgia, 6010
- Research Site
-
Tbilisi, Georgia, 0144
- Research Site
-
Tbilisi, Georgia, 0112
- Research Site
-
Tbilisi, Georgia, '0159
- Research Site
-
Tbilisi, Georgia, 186
- Research Site
-
Tbilisi, Georgia, 0114
- Research Site
-
-
-
-
-
Athens, Grecia, 115 27
- Research Site
-
Athens, Grecia, 12462
- Research Site
-
Elaiones, Grecia, 546 23
- Research Site
-
Piraeus, Grecia, 185 47
- Research Site
-
Thessaloniki, Grecia, 57001
- Research Site
-
-
-
-
-
Genoa, Italia, 16132
- Research Site
-
Meldola, Italia, 47014
- Research Site
-
Milan, Italia, 20133
- Research Site
-
Naples, Italia, 80131
- Research Site
-
Orbassano, Italia, 10043
- Research Site
-
Perugia, Italia, 06132
- Research Site
-
Rozzano, Italia, 20089
- Research Site
-
Udine, Italia, 33100
- Research Site
-
Verona, Italia, 37134
- Research Site
-
-
-
-
-
Kuala Lumpur, Malasia, 59100
- Research Site
-
Kuching, Malasia, 93586
- Research Site
-
Perai, Malasia, 13700
- Research Site
-
-
-
-
-
Beijing, Porcelana, 100730
- Research Site
-
Hangzhou, Porcelana, 310014
- Research Site
-
Jinan, Porcelana, 250013
- Research Site
-
Yantai, Porcelana, 264000
- Research Site
-
Zhengzhou, Porcelana, 450000
- Research Site
-
-
-
-
-
Lisbon, Portugal, 1649-035
- Research Site
-
Lisbon, Portugal, 1169-050
- Research Site
-
Lisbon, Portugal, 1400-038
- Research Site
-
Porto, Portugal, 4099-001
- Research Site
-
-
-
-
-
Cluj-Napoca, Rumania, 400641
- Research Site
-
Craiova, Rumania, 200542
- Research Site
-
Floreşti, Rumania, 407280
- Research Site
-
-
-
-
-
Belgrade, Serbia, 11000
- Research Site
-
-
-
-
-
Geneva, Suiza, 1205
- Research Site
-
Lausanne, Suiza, 1011
- Research Site
-
Winterthur, Suiza, 8401
- Research Site
-
Zurich, Suiza, 8091
- Research Site
-
-
-
-
-
Changhua, Taiwán, 50006
- Research Site
-
New Taipei City, Taiwán, 23561
- Research Site
-
Taipei, Taiwán, 106
- Research Site
-
Taipei, Taiwán, 110
- Research Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Key Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 with no deterioration.
- Life expectancy greater than or equal to (>=) 12 weeks.
- Adequate organ and bone marrow function.
- Body weight greater than (>) 35 kilograms (kg) at screening and at randomization.
- Histologically or cytologically documented NSQ NSCLC in substudy 1 and SQ or NSQ mNSCLC in substudy 2.
- Absence of sensitizing epidermal growth factor receptor (EGFR) mutations.
- Absence of documented tumor genomic alteration results from tests conducted as part of standard local practice in any other actionable driver oncogenes for which there are locally approved targeted 1L therapies.
- At least one measurable lesion not previously irradiated that can be accurately measured at baseline as >= 10 millimeter (mm) in the longest diameter.
Key Exclusion Criteria:
- Spinal cord compression.
- History of primary active immunodeficiency.
- Active or prior documented autoimmune or inflammatory disorders.
- Mixed small-cell lung cancer and NSCLC histology or sarcomatoid variant.
- Brain metastases unless asymptomatic, stable, and not requiring steroids for at least 14 days prior to start of study intervention. A minimum of 2 weeks must have elapsed between the end of radiation therapy and study enrollment.
- Prior chemotherapy or any other systemic therapy for Stage IV NSCLC. Participants who have received prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for local disease are eligible, provided that progression has occurred greater (>) 12 months from end of last therapy.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Substudy 1: Arm 1A: Volrustomig dose regimen 1 + Carboplatin and Pemetrexed
Volrustomig priming dose followed by volrustomig dosing regimen 1 in combination with carboplatin and pemetrexed. |
Participants will receive volrustomig via intravenous (IV) infusion.
Otros nombres:
Participants will receive carboplatin via IV infusion. Participants will receive pemetrexed via IV infusion. |
|
Experimental: Substudy 1: Arm 1B: Volrustomig dose regimen 2 + Carboplatin and Pemetrexed
Volrustomig priming dose followed by volrustomig dosing regimen 2 in combination with carboplatin and pemetrexed. |
Participants will receive volrustomig via intravenous (IV) infusion.
Otros nombres:
Participants will receive carboplatin via IV infusion. Participants will receive pemetrexed via IV infusion. |
|
Experimental: Substudy 2: Arm 2A: Volrustomig dose regimen 2 +Ramucirumab + Carboplatin + Pemetrexed or Paclitaxel
Volrustomig priming dose followed by volrustomig dosing regimen 2 in combination with ramucirumab and histology-specific chemotherapy (carboplatin+ either pemetrexed or paclitaxel). |
Participants will receive volrustomig via intravenous (IV) infusion.
Otros nombres:
Participants will receive carboplatin via IV infusion. Participants will receive pemetrexed via IV infusion. Participants will receive ramucirumab via IV infusion. Participants will receive paclitaxel via IV infusion. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Periodo de tiempo: From screening (Days -28 to Day -1) up to 2 year 10 months
|
The safety and tolerability of volrustomig in combination with other anticancer drugs in participants with specified solid tumors will be assessed. |
From screening (Days -28 to Day -1) up to 2 year 10 months
|
|
Confirmed Objective Response rate (ORR)
Periodo de tiempo: Up to 2 year 10 months
|
ORR is defined as the percentage of participants who have a confirmed complete response (CR) or confirmed partial response (PR), as per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1). |
Up to 2 year 10 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Disease Control Rate (DCR)
Periodo de tiempo: Up to 2 year 10 months
|
DCR is defined as the percentage of participants who have a CR or PR or who have stable disease (SD) after the date of randomization or first dose. |
Up to 2 year 10 months
|
|
Duration of Response (DOR)
Periodo de tiempo: Up to 2 year 10 months
|
DOR is defined as the time from the date of first documented response until the date of documented progression or death due to any cause (in the absence of progression). |
Up to 2 year 10 months
|
|
Progression Free Survival (PFS)
Periodo de tiempo: Up to 2 year 10 months
|
PFS is defined as the time from randomization or first dose until radiological progression or death due to any cause (in the absence of progression). |
Up to 2 year 10 months
|
|
Overall Survival (OS)
Periodo de tiempo: Up to 2 year 10 months
|
OS is defined as the time from randomization or first dose until the date of death due to any cause. |
Up to 2 year 10 months
|
|
Serum Concentration of Volrustomig
Periodo de tiempo: Up to 2 year 10 months
|
The serum concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. |
Up to 2 year 10 months
|
|
Trough concentration (Ctrough)
Periodo de tiempo: Up to 2 year 10 months
|
The trough concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. |
Up to 2 year 10 months
|
|
Maximum Observed Concentration (Cmax)
Periodo de tiempo: Up to 2 year 10 months
|
The serum concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. |
Up to 2 year 10 months
|
|
Area Under the Curve (AUC)
Periodo de tiempo: Up to 2 year 10 months
|
The AUC concentrations of volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. |
Up to 2 year 10 months
|
|
Number of Participants with Positive Antidrug Antibodies (ADAs)
Periodo de tiempo: Up to 2 year 10 months
|
The incidence of ADAs against volrustomig or other anticancer agents in serum will be assessed. |
Up to 2 year 10 months
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Neoplasias por sitio
- Neoplasias
- Enfermedades de las vías respiratorias
- Enfermedades pulmonares
- Neoplasias de las vías respiratorias
- Neoplasias torácicas
- Neoplasias Pulmonares
- Carcinoma Broncogénico
- Neoplasias Bronquiales
- Carcinoma de pulmón de células no pequeñas
- Aminoácidos, péptidos y proteínas
- Proteínas
- Químicos orgánicos
- Compuestos heterocíclicos
- Compuestos heterocíclicos, 2 anillos
- Compuestos heterocíclicos, anillo fusionado
- Hidrocarburos
- Cicloparafinas
- Hidrocarburos, alicíclicos
- Hidrocarburos, cíclico
- Terpenos
- Anticuerpos, monoclonales, humanizados
- Anticuerpos, monoclonal
- Anticuerpos
- Inmunoglobulinas
- Inmunoproteínas
- Proteínas de la sangre
- Globulinas séricas
- Globulinas
- Complejos de coordinación
- Guanina
- Hipoxantino
- Purinones
- Purinas
- Glutamatos
- Aminoácidos, ácido
- Aminoácidos
- Aminoácidos, dicarboxílico
- Taxaides
- Ciclodecanos
- Diterpenos
- Pemetrexed
- Ramucirumab
- Carboplatino
- Paclitaxel
Otros números de identificación del estudio
- D798KC00001
- 2023-509482-20-00 (Identificador de registro: CTIS)
- 2023 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Qualified researchers can request access to anonymized individual patient-leveldata from AstraZeneca group of companies sponsored clinical trials via therequest portal Vivli.org. All requests will be evaluated as per the AZ disclosurecommitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes",indicates that AZ are accepting requests for IPD, but this does not mean allrequests will be approved.
Marco de tiempo para compartir IPD
AstraZeneca will meet or exceed data availability as per the commitment smade to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment athttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Criterios de acceso compartido de IPD
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure researchenvironmentVivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .